“…They further stated that if procedural safety was based merely on the incidence of bleeding complication, then the study of Lillis et al might be interpreted as evidence of increased bleeding risk in patients on single and dual antiplatelet therapy particularly for dual therapy. However, if additional meaningful clinical parameters such as time frame of occurrence of increased bleeding and efficacy of local hemostatic measures to control bleeding are added, then the results can be interpreted differently; that is, patients on antiplatelet therapy have increased incidence of prolonged bleeding when compared to control group, but the increased bleeding was presented in the time frame of safe clinical setting and can be easily controlled by local hemostatic measures [65]. …”